• AG真人国际-(china)官方网站

    日本語

    Our Mission
    Inclusive and Open to Diversity,
    Innovationoriented to Win Together
    and Benefit the Mankind

    Haihe Biopharma
    Pioneering the Future
    of Original
    Oncology Drugs

    Haihe Stories
    Our Scientists

    Haihe Mission

    Our Mission and Purpose

    Research and Development

    More R&D Pipelines

    Haihe Stories

    Our Scientists

    About Us

    • Established in

      2011

    • Headquartered in

      Pudong

      Shanghai

      China

    • China

      Indigenous

      Innovative

      Biopharma

      Company

    • Specializing in the Discovery,

      Development, Production

      and Commercialization

      Innovative Oncology

      Drugs

    • Academician1

      Scientists141

      Doctorate
      Degree      29

      Number of
      Employees      233

      Master’s
      Degree      61


      As of FEB.29,2024

    • Core Products

      in R&D Pipeline

      10+

     
    R&D Field
    Strong, Innovation-driven R&D Capabilities
    • Have obtained multiple proprietary global intellectual property rights
    • Multiple global clinical research projects are ongoing simultaneously
    • Have been recognized by authoritative industry institutions
    Cancer Types Covered by the R&D Pipeline
    Lung Cancer
    Breast Cancer
    Gastric Cancer
    Gynecological Cancer
    Hematologic Malignancies
    Rich and Balanced Pipeline
    • 1 product – Gumarontinib, an oral highly selective mesenchymal-epithelial transition (MET) inhibitor and a Category 1 innovative new chemical drug has been conditionally approved by NMPA that Haihe owns its global intellectual property rights.
    • 10+ Oncology+Non-oncology compounds in core pipeline, including those in late clinical stage and pre-clinical stage
    • Multiple potential best-in-class compounds are expected to be used in monotherapy or combination to treat major indications
    Company Milestones

    Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. 

    •  

      March 2023

      Haihe Biopharma’s Gumarontinib has been approved by NMPA

    •  

      March 2022

       NMPA-CDE Grants Priority Review Designation to Haihe Biopharma's Gumarontinib

    •  

      February 2022

      The NDA for Haihe Biopharma’s Gumarontinib has been accepted for review by the CDE.

    •  

      March 2021

      Haihe established its Japan office

    •  

      July 2020

      Haihe completed worth
      1.2 billion yuan Series B Funding

       

    •  

      July 2020

      Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Shanghai RMX Biopharma Co Ltd.

    •  

      December 2019

      Haihe established its US office

    •  

      October 2019

      Haihe’s Manufacturing Hub set foot in Taizhou China Medical City, with planned investment of 600 million yuan

    •  

      April 2019

      Haihe completed the first patient dosing of oral paclitaxel RMX3001 phase III clinical trial for advanced gastric cancer

    •  

      February 2019

      Haihe completed Haihe completed $136.6 million Series A Funding

    •  

      September 2018

      Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical

    •  

      March 2018

      Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.

    Interviews
    I am glad that some research achievements in China in the field of oncology drugs have already been on par with global leaders. Especially in personalized research, China is carrying out projects concurrently with the world, and striving to be a leader in certain aspects.

    Academician Jian Ding:
    Make Good Drugs that Ordinary People Can Afford

    （Xinmin Evening News，2020-11-18）

    Read More
     
    I often tell myself to work hard and seize every opportunity. I also often inspire my team to develop good drugs that ordinary people can afford, so that new drugs created by Chinese scientists will come onto the global stage as soon as possible.
    News Center
    Join Us
    Let’s ride the wave of developing original innovative drugs in China. Haihe Biopharma aspires to become one of the companies that R&D professionals and outstanding managers have the strongest desire to join.
    Follow Us
    ©2020 Haihe Biopharma Co., Ltd.
    All Rights Reserved 沪ICP备12016151号-1
    友情链接: